Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects

por Rosen, Jeffrey B, Jimenez, Jose G, Pirags, Valdis, Vides, Hella, Massaad, Rachid, Hanson, Mary E, Brudi, Philippe, Triscari, Joseph
Publicado 2013

Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, mult...

por Hing Ling, Paul Kah, Civeira, Fernando, Dan, Andrei Gheorghe, Hanson, Mary E, Massaad, Rachid, De Tilleghem, Celine Le Bailly, Milardo, Christopher, Triscari, Joseph
Publicado 2012

Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes

por Brinton, Eliot A., Triscari, Joseph, Brudi, Philippe, Chen, Erluo, Johnson-Levonas, Amy O., Sisk, Christine McCrary, Ruck, Rae Ann, MacLean, Alexandra A., Maccubbin, Darbie, Mitchel, Yale B.
Publicado 2016

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control

por Bays, Harold E, Brinton, Eliot A, Triscari, Joseph, Chen, Erluo, Maccubbin, Darbie, MacLean, Alexandra A, Gibson, Kendra L, Ruck, Rae Ann, Johnson-Levonas, Amy O, O’Neill, Edward A, Mitchel, Yale B
Publicado 2015